AAAAAA

   
Results: 1-8 |
Results: 8
RESPONSE OF CD4 LYMPHOCYTES AND CLINICAL CONSEQUENCES OF TREATMENT USING DDI OR DDC IN PATIENTS WITH ADVANCED HIV-INFECTION
Authors: GOLDMAN AI CARLIN BP CRANE LR LAUNER C KORVICK JA DEYTON L ABRAMS DI
Citation: Ai. Goldman et al., RESPONSE OF CD4 LYMPHOCYTES AND CLINICAL CONSEQUENCES OF TREATMENT USING DDI OR DDC IN PATIENTS WITH ADVANCED HIV-INFECTION, Journal of acquired immune deficiency syndromes and human retrovirology, 11(2), 1996, pp. 161-169
CD4(-LYMPHOCYTE COUNTS AND PATTERNS OF MORTALITY AMONG PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS WHO WERE ENROLLED IN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDS() T)
Authors: SARAVOLATZ L NEATON JD SACKS L DEYTON L RHAME F SHERER R
Citation: L. Saravolatz et al., CD4(-LYMPHOCYTE COUNTS AND PATTERNS OF MORTALITY AMONG PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS WHO WERE ENROLLED IN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDS() T), Clinical infectious diseases, 22(3), 1996, pp. 513-520
IMPORTANCE OF SURROGATE MARKERS IN EVALUATION OF ANTIVIRAL THERAPY FOR HIV-INFECTION
Authors: DEYTON L
Citation: L. Deyton, IMPORTANCE OF SURROGATE MARKERS IN EVALUATION OF ANTIVIRAL THERAPY FOR HIV-INFECTION, JAMA, the journal of the American Medical Association, 276(2), 1996, pp. 159-160
CONSIDERATIONS IN CHOICE OF A CLINICAL END-POINT FOR AIDS CLINICAL-TRIALS
Authors: NEATON JD WENTWORTH DN RHAME F HOGAN C ABRAMS DI DEYTON L
Citation: Jd. Neaton et al., CONSIDERATIONS IN CHOICE OF A CLINICAL END-POINT FOR AIDS CLINICAL-TRIALS, Statistics in medicine, 13(19-20), 1994, pp. 2107-2125
SURVIVAL AND DISEASE PROGRESSION ACCORDING TO GENDER OF PATIENTS WITHHIV-INFECTION - THE TERRY-BEIRN-COMMUNITY-PROGRAMS FOR CLINICAL RESEARCH ON AIDS
Authors: MELNICK SL SHERER R LOUIS TA HILLMAN D RODRIGUEZ EM LACKMAN C CAPPS L BROWN LS CARLYN M KORVICK JA DEYTON L
Citation: Sl. Melnick et al., SURVIVAL AND DISEASE PROGRESSION ACCORDING TO GENDER OF PATIENTS WITHHIV-INFECTION - THE TERRY-BEIRN-COMMUNITY-PROGRAMS FOR CLINICAL RESEARCH ON AIDS, JAMA, the journal of the American Medical Association, 272(24), 1994, pp. 1915-1921
A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITHZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
Authors: ABRAMS DI GOLDMAN AI LAUNER C KORVICK JA NEATON JD CRANE LR GRODESKY M WAKEFIELD S MUTH K KORNEGAY S COHN DL HARRIS A LUSKINHAWK R MARKOWITZ N SAMPSON JH THOMPSON M DEYTON L
Citation: Di. Abrams et al., A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITHZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, The New England journal of medicine, 330(10), 1994, pp. 657-662
PRIMARY PROPHYLAXIS WITH PYRIMETHAMINE FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - RESULTS OF A RANDOMIZED TRIAL
Authors: JACOBSON MA BESCH CL CHILD C HAFNER R MATTS JP MUTH K WENTWORTH DN NEATON JD ABRAMS D RIMLAND D PEREZ G GRANT IH SARAVOLATZ LD BROWN LS DEYTON L
Citation: Ma. Jacobson et al., PRIMARY PROPHYLAXIS WITH PYRIMETHAMINE FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - RESULTS OF A RANDOMIZED TRIAL, The Journal of infectious diseases, 169(2), 1994, pp. 384-394
THE UTILITY OF 2-STAGE TUBERCULIN (PPD) SKIN TESTING IN INDIVIDUALS WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION
Authors: GORDIN F THOMPSON C MATTS J MUTH K KORVICK J DEYTON L
Citation: F. Gordin et al., THE UTILITY OF 2-STAGE TUBERCULIN (PPD) SKIN TESTING IN INDIVIDUALS WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION, The American review of respiratory disease, 147(4), 1993, pp. 487-487
Risultati: 1-8 |